[{"data":1,"prerenderedAt":193},["ShallowReactive",2],{"drug-milnacipran":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":12,"synonyms":16,"formulations":20,"regimens":59,"contraindications":85,"warnings":95,"renal":110,"monitoring":120,"interactions":121,"review":122,"examples":125,"atc":131,"iran":133,"usApproval":145,"links":151,"populations":167},"milnacipran",1,{"fa":7,"en":8},"میلناسیپران","Milnacipran","nervous-system",{"fa":11,"en":11},"SNRI",[13],{"name":14,"market":15},"Savella","US",[17,18,19,7],"savella","ساولا","ixel",[21,35,43,51],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[15],[32],{"source":33,"section":34},"fda-savella","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-25","25 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},25,[15],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-100","100 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},100,[15],[50],{"source":33,"section":34},{"id":52,"form":23,"route":24,"label":53,"concentration":54,"markets":56,"refs":57},"tab-12-5","12.5 mg tablet",{"amount":55,"unit":28,"perUnit":23,"scored":29},12.5,[15],[58],{"source":33,"section":34},[60],{"id":61,"disease":62,"label":63,"population":66,"type":70,"unit":28,"dose":71,"refs":73,"notes":76},"fm","fibromyalgia",{"fa":64,"en":65},"فیبرومیالژی بزرگسال — ۵۰ mg دو بار در روز (تا ۱۰۰ mg دو بار)","Fibromyalgia, adults — 50 mg twice daily (up to 100 mg twice daily)",{"minAge":67},{"value":68,"unit":69},18,"year","fixed",{"perDose":27,"perDoseMax":47,"dosesPerDay":72},2,[74],{"source":33,"section":75},"2.1",[77],{"text":78,"refs":81},{"fa":79,"en":80},"تیتراسیون: روز ۱: ۱۲٫۵ mg؛ روز ۲–۳: ۱۲٫۵ mg دو بار؛ روز ۴–۷: ۲۵ mg دو بار؛ سپس ۵۰ mg دو بار. با غذا بهتر تحمل می‌شود. قطع تدریجی.","Titration: day 1: 12.5 mg; days 2–3: 12.5 mg twice; days 4–7: 25 mg twice; then 50 mg twice daily. Better tolerated with food. Taper when stopping.",[82,83],{"source":33,"section":75},{"source":33,"section":84},"2.4",[86],{"id":87,"severity":88,"text":89,"refs":92},"maoi","block",{"fa":90,"en":91},"مهارکننده MAO همزمان، ظرف ۱۴ روز پس از قطع آن، یا ظرف 5 روز پس از قطع این دارو؛ لینزولید یا متیلن بلو وریدی (سندرم سروتونین).","MAOIs concomitantly, within 14 days of stopping them, or within 5 days of stopping this drug; linezolid or IV methylene blue (serotonin syndrome).",[93],{"source":33,"section":94},"4.1",[96,103],{"text":97,"refs":100},{"fa":98,"en":99},"هشدار جعبه‌ای: خطر خودکشی با ضدافسردگی‌ها در کودکان و جوانان؛ برای افسردگی در آمریکا تأیید نشده.","Boxed warning: suicidality with antidepressants in children and young adults; not approved for depression in the US.",[101],{"source":33,"section":102},"Boxed Warning",{"text":104,"refs":107},{"fa":105,"en":106},"سندرم سروتونین؛ افزایش فشار و ضربان؛ تشنج؛ سمیت کبد؛ هیپوناترمی؛ خونریزی؛ فعال شدن مانیا.","Serotonin syndrome; raised blood pressure and heart rate; seizures; hepatotoxicity; hyponatraemia; bleeding; activation of mania.",[108],{"source":33,"section":109},"5",[111],{"egfrBelow":112,"severity":113,"text":114,"refs":117},30,"warn",{"fa":115,"en":116},"ClCr ۵ تا ۲۹: نگهدارنده ۵۰٪ کم (۲۵ mg دو بار)؛ ESRD توصیه نمی‌شود.","CrCl 5–29: reduce maintenance by 50% (25 mg twice daily); ESRD not recommended.",[118],{"source":33,"section":119},"2.2",[],[],{"status":123,"reviewer":124,"date":124},"unverified",null,[126],{"regimen":61,"formulation":22,"input":127,"expect":130},{"ageYears":128,"weightKg":129},45,70,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":47},[132],"N06AX17",{"status":134,"forms":135,"refs":140},"registered",[136],{"code":137,"en":138,"fa":139},"13179","MILNACIPRAM 25MG TAB","قرص میلناسیپرام ۲۵ میلی‌گرم",[141],{"source":142,"section":143,"url":144},"darooyab-generic","G-596\u002FMilnacipran","https:\u002F\u002Fwww.darooyab.ir\u002FG-596\u002FMilnacipran",{"kind":146,"refs":147,"id":150},"NDA",[148],{"source":33,"section":149},"SPL approval \u002F marketing category","NDA022256",[152,155,159,162,165],{"kind":153,"url":154,"label":150},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022256",{"kind":156,"url":157,"label":158},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=16a4a314-f97e-4e91-95e9-576a3773d284","FDA Savella",{"kind":160,"url":161,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609016.html",{"kind":163,"url":164,"label":132},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AX17",{"kind":166,"url":144,"label":8},"darooyab",{"pregnancy":168,"pediatric":177,"geriatric":185},{"level":169,"text":170,"quote":173,"refs":174},"caution",{"fa":171,"en":172},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on data from published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions ( 5.2 )] .",[175],{"source":33,"section":176},"8.1",{"level":178,"text":179,"quote":182,"refs":183},"avoid",{"fa":180,"en":181},"هشدار جعبه‌ای برچسب درباره کودکان.","Boxed warning in the label about children.","SAVELLA is not approved for use in pediatric patients [see Indications and Usage ( 1 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )].",[184],{"source":33,"section":102},{"level":169,"text":186,"quote":189,"refs":190},{"fa":187,"en":188},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","SNRIs, SSRIs, and SAVELLA, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions ( 5.8 )] .",[191],{"source":33,"section":192},"8.5",1792191555564]